Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to demonstrate the efficacy of T1225 eye drops versus placebo eye drops on the global ocular discomfort (VAS).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laboratoires Thea
• Collaborators: Keyrus; Keyrus Biopharma; VEEDA
• Treatments: Azithromycin; Ophthalmic Solutions; Povidone; Tetrahydrozoline

Criteria

Inclusion Criteria:

-Diagnosis of moderate to severe chronic blepharitis (posterior and/or anterior) in at least one eligible eye

Exclusion Criteria:

• Monophtalmia

• Eyelid dysfunction

• Facial paralysis.

• Severe dry eye syndrome.

• Ocular metaplasia.

• Filamentous keratitis

• Schirmer test < 5 mm.

• Best far corrected visual acuity < 1/10.